Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hikma Pharmaceuticals (GB:HIK)
:HIK
Holding GB:HIK?
Track your performance easily
HIK Stock Chart & Stats
Day’s Range― - ―
52-Week Range1,750.00p - 2,165.00p
Previous CloseN/A
Volume7.28K
Average Volume (3M)362.87K
Market Cap
£4.63B
Enterprise Value5.05B
Total Cash (Recent Filing)$175.00M
Total Debt (Recent Filing)$742.00M
Price to Earnings (P/E)20.5
Beta0.79
Next Earnings
Feb 20, 2025EPS EstimateN/A
Last Dividend Ex-Date
Aug 15, 2024Dividend Yield2.97%
Share Statistics
EPS (TTM)1.02
Shares Outstanding221,886,460
10 Day Avg. Volume398,095
30 Day Avg. Volume362,869
Standard Deviation0.08
R-Squared0.03
Alpha0.00412
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.87
Price to Cash Flow (P/CF)14.30
P/FCF Ratio19.70
Enterprise Value/Market Cap1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.63
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
2,495.00pPrice Target Upside19.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Hikma Pharmaceuticals News
PremiumCompany Announcements
Hikma Pharmaceuticals Discloses PDMR Share Disposal
PremiumCompany Announcements
Hikma Pharmaceuticals Reappoints PwC as Auditor
PremiumCompany Announcements
Hikma Pharmaceuticals Projects Strong Growth for 2024
PremiumCompany Announcements
Hikma Pharmaceuticals Faces Shareholder Opposition on Buyback Waiver
PremiumCompany Announcements
Hikma Executives Invest in Company Shares
PremiumCompany Announcements
Hikma Pharmaceuticals Expands with Xellia Acquisition
PremiumCompany Announcements
Hikma Executive Sells Shares Worth £888.5K
Options Prices
Currently, No data available
---
Ownership Overview
7.66% Insiders
5.07% Mutual Funds
― Other Institutional Investors
78.74% Public Companies and
Individual Investors
HIK FAQ
What was Hikma Pharmaceuticals’s price range in the past 12 months?
Hikma Pharmaceuticals lowest share price was 1750.00p and its highest was 2165.00p in the past 12 months.
What is Hikma Pharmaceuticals’s market cap?
Hikma Pharmaceuticals’s market cap is £4.63B.
When is Hikma Pharmaceuticals’s upcoming earnings report date?
Hikma Pharmaceuticals’s upcoming earnings report date is Feb 20, 2025 which is in 29 days.
How were Hikma Pharmaceuticals’s earnings last quarter?
Hikma Pharmaceuticals released its earnings results on Aug 08, 2024. The company reported 1.042p earnings per share for the quarter, beating the consensus estimate of N/A by 1.042p.
Is Hikma Pharmaceuticals overvalued?
According to Wall Street analysts Hikma Pharmaceuticals’s price is currently Undervalued.
Does Hikma Pharmaceuticals pay dividends?
Hikma Pharmaceuticals pays a Annually dividend of 62.403p which represents an annual dividend yield of 2.97%. See more information on Hikma Pharmaceuticals dividends here
What is Hikma Pharmaceuticals’s EPS estimate?
Hikma Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikma Pharmaceuticals have?
Hikma Pharmaceuticals has 221,886,460 shares outstanding.
What happened to Hikma Pharmaceuticals’s price movement after its last earnings report?
Hikma Pharmaceuticals reported an EPS of 1.042p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 8.261%.
Which hedge fund is a major shareholder of Hikma Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:HIK
---
Hikma Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
2,495.00p (19.61% Upside)
2,495.00p (19.61% Upside)
Blogger Sentiment
Bullish
GB:HIK Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth £64.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.52%
12-Months-Change
Fundamentals
Return on Equity
12.79%
Trailing 12-Months
Asset Growth
5.54%
Trailing 12-Months
Company Description
Hikma Pharmaceuticals
Founded in the Middle East and with headquarters in London, Hikma manufactures generic and in-licensed pharmaceuticals. The firm operates in three segments: injectables, generics, branded, and other, which comprise most of the company's revenue at about 41%, 33%, and 26%, respectively. About 62%, 33%, and 6% of Hikma's sales are based in the U.S., Middle East, North Africa, and Europe, and Other.
---
HIK Stock 12 Month Forecast
Average Price Target
2,495.00p
▲(19.61% Upside)
Technical Analysis
GlaxoSmithKline
―
AstraZeneca
―
Indivior
―
PureTech Health
―
RUA Life Sciences
―
Alliance Pharma
―
Best Analysts Covering HIK
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+7.16%
assigned a buy rating 6 months ago
Copying Peter Verdult's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +7.16% per trade.
---